ISHBT

PROFICIENCY TESTING REPORT
ISHTM-AIIMS EXTERNAL QUALITY ASSURANCE PROGRAMME
NABL accredited program as per ISO/IEC 17043:2010 standard
Organized By Department of Hematology, AIIMS, New Delhi-110029

NABL Certificate No.
PC - 1002

Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens

EQAP CODE No. : 1120   **Distribution No.:** 153-D   **Month/Year:** August/2021
Instrument ID: SYSMEX XN 3100
Name & Contact No. of PT Co-ordinator: Dr. Seema Tyagi (Prof.), Hematology, AIIMS, Delhi,
Tel: 9013085730 , E-Mail : accuracy2000@gmail.com
Date of issue & status of the report: 13-09-2021[Final].

CBC and Retic Assessment

Test Parameters	S.No.	Among Lab (Accuracy Testing)						Within Lab (Precision Testing)			
		Your Result 1	Your Result 2	Your Results Sum of 2 Value	Consensus result sum of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score	Yours Results Diff. of 2 Values	Consensus Result Diff. of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score
WBC x10^3/μl	1	2.6	2.57	5.17	5.5	0.0230	-0.57	0.03	0.08	0.0050	-0.75
RBC x10^6/μl	1	3.93	3.92	7.85	7.54	0.0070	1.67	0.01	0.03	0.0020	-0.54
Hb g/dl	1	12.4	12.2	24.6	23.8	0.0200	1.54	0.2	0.1	0.0070	1.35
HCT%	1	38.9	38.7	77.6	74.3	0.1290	0.90	0.2	0.3	0.0230	-0.27
MCV-fl	1	99	98.7	197.7	196.6	0.2900	0.13	0.3	0.3	0.0250	0.00
MCH-Pg	1	31.6	31.1	62.7	63.1	0.0300	-0.26	0.5	0.2	0.0160	1.35
MCHC-g/dl	1	31.9	31.5	63.4	64.2	0.1170	-0.25	0.4	0.2	0.0170	0.90
Plt. x10^3/μl	1	125	123	248	222	1.09	0.82	2	4	0.28	-0.39
Retic %	2	1.9	1.6	3.5	1.2	0.03	2.82	0.3	0.1	0.01	2.70

P.S . Assesment

Approved By -

Incharge
CCL- Biochemistry
PMT, RMC, Loni

		YOUR REPORT	CONSENSUS REPORT
DLC%	3	Nrbcs=- , Poly=33% L=3%, E=3%, Mono/Promono=0 , B1=3% P.M.=6%, Mye=40%, Meta=11%, Other=Basophils 1%.	Poly: 40 – 60, Myelo: 10 - 25, Meta: 5 - 20, Promyelo: 1-10, nRBC/Lympho/Blast/Eos/Baso/Mono: 0 - 5
RBC Morphology	3	Microcytes +	Predominantly: Normocytic/Normochromic; Moderate: Anisocytosis, hypochromia, Microcytosis; Mild: Macrocytosis, Poikilocytosis
Diagnosis	3	Chronic Myeloid Leukemia (Chronic phase).	Chronic Myeloid Leukemia (Chronic Phase)

EQAP Code No.: 1120 Distribution No.: 153-D Month/Year: August/2021 Instrument ID: SYSMEX XN 3100

COMBINED DATA VALUES OF TOTAL PARTICIPANTS

Test parameters	S.No.	Total participants covered in the current dist.	Total No. responded	% of Labs with Z Score 0-2		% of Labs with Z Score 2-3		% of Labs with Z Score >3	
				Among labs	Within lab	Among labs	Within lab	Among labs	Within lab
WBC x10^3/µl	1	317	315	84.76	87.94	3.49	1.59	11.75	9.84
RBC x10^6/µl	1	317	315	92.7	91.11	4.13	3.81	3.17	4.76
Hb g/dl	1	317	315	88.25	91.75	6.67	0.32	5.08	4.44
HCT%	1	317	315	95.24	90.16	2.22	3.49	2.54	6.03
MCV-fl	1	317	315	96.51	92.7	2.22	3.17	1.27	4.13
MCH-Pg	1	317	315	88.57	91.75	8.25	3.49	3.17	4.76
MCHC-g/dl	1	317	315	94.6	88.25	3.49	3.17	1.9	8.57
Plt. x10^3/µl	1	317	315	93.33	90.48	4.44	4.13	2.22	5.4
ReticCount%	2	317	283	90.46	87.63	4.95	6.71	3.89	5.65
PS Assessment	3	317	296	Acceptable:98.65%,Warning Signal:1.35%,Unacceptable :0%					

Comments:

1). Among Lab (EQA) : Results acceptable.

2). Within Lab (IQA) : Precision acceptable.

Note-1: EQA (External Quality Assurance) : Your Performance among various of participating labs in PT, to determine the accuracy of your results.

IQA (Internal Quality Assurance) : Your Performance of comparison of two consecutive measurement values within your lab to test the precision of your autoanalyzer.

Note-2: Z score among & within lab were calculated, as per to ISO/IEC 13528:2015 standard. Z score among lab (EQA)= (Your Result Sum of two values – Consensus Result sum of two values)/(Normalised IQR)

 Z score within lab (IQA)= (Your Result Difference of two values – Consensus Result difference of two values)/(Normalised IQR)

 IQR = Quartile 3 - Quartile 1 of participant data, Normalised IQR = 0.7413 x IQR

Note-3: Z score 0 to ±2: Acceptable, Z score ±2 to ±3 :Warning Signal, Z score > ±3 : Unacceptable [As per ISO/IEC 13528:2015 standard]

Note-4: Z score value between"0 to ±2" are texted in green colour. Z score value between"±2 to ±3" are texted in orange colour. Z score value > ±3 are texted in red colour.

Note-5: Homogeneity and stability testing of PT sample were done as per ISO 13528:2015 standard. To pass homogeneity test, between sample SD (Ss) should be smaller than the check value (0.3*SDPA). To pass the stability test, average difference in measurement values of first and last day sample (x̄-ȳ) should be smaller than the check value (0.3*SDPA).

Note-6: ISHTM-AIIMS-EQAP does not subcontract any task of its scheme

Note-7: Participants are free to use methods/analyzer of their own choice.

Note-8: Proficiency testing (PT) samples are sent quarterly to each participant.

Note-9: All the necessary details regarding design and implementation of PT, are provided in the instruction sheet as well as on programme's website www.ishtmaiimseqap.com.

Report authorized by,

Dr. Seema Tyagi (Prof.)
PT Co-ordinator: ISHTM-AIIMS-EQAP
Department of Hematology, AIIMS, New Delhi

-----------End Of Report-----------

PROFICIENCY TESTING REPORT
ISHTM-AIIMS EXTERNAL QUALITY ASSURANCE PROGRAMME
NABL accredited program as per ISO/IEC 17043:2010 standard
Organized By Department of Hematology, AIIMS, New Delhi-110029

ISHBT

NABL Certificate No.
PC - 1002

Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens

EQAP CODE No. : 1120 **Distribution No.:** 153-D **Month/Year:** August/2021

Instrument ID: SYSMEX XN 3100

Name & Contact No. of PT Co-ordinator: Dr. Seema Tyagi (Prof.), Hematology, AIIMS, Delhi,
Tel: 9013085730 , E-Mail : accuracy2000@gmail.com

Date of issue & status of the report: 13-09-2021[Final].

CBC and Retic Assessment

Test Parameters	S.No.	Among Lab (Accuracy Testing)						Within Lab (Precision Testing)			
		Your Result 1	Your Result 2	Your Results Sum of 2 Value	Consensus result sum of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score	Yours Results Diff. of 2 Values	Consensus Result Diff. of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score
WBC x10³/µl	1	2.6	2.57	5.17	5.5	0.0230	-0.57	0.03	0.08	0.0050	-0.75
REC x10⁶/µl	1	3.93	3.92	7.85	7.54	0.0070	1.67	0.01	0.03	0.0020	-0.54
Hb g/dl	1	12.4	12.2	24.6	23.8	0.0200	1.54	0.2	0.1	0.0070	1.35
HCT%	1	38.9	38.7	77.6	74.3	0.1290	0.90	0.2	0.3	0.0230	-0.27
MCV-fl	1	99	98.7	197.7	196.6	0.2900	0.13	0.3	0.3	0.0250	0.00
MCH-Pg	1	31.6	31.1	62.7	63.1	0.0300	-0.26	0.5	0.2	0.0160	1.35
MCHC-g/dl	1	31.9	31.5	63.4	64.2	0.1170	-0.25	0.4	0.2	0.0170	0.90
Plt. x10³/µl	1	125	123	248	222	1.09	0.82	2	4	0.28	-0.39
Retic %	2	1.9	1.6	3.5	1.2	0.03	2.82	0.3	0.1	0.01	2.70

Approved By -
S.N.Jou
Incharge
CCL- Biochemistry
PMP, RMC, Loni

P.S . Assesment

		YOUR REPORT	CONSENSUS REPORT
DLC%	3	Nrbcs=- , Poly=33% L=3%, E=3%, Mono/Promono=0 , B1=3% P.M.=6%, Mye=40%, Meta=11%, Other=Basophils - 1%.	Poly: 40 - 60, Myelo: 10 - 25, Meta: 5 - 20, Promyelo: 1-10, nRBC/Lympho/Blast/Eos/Baso/Mono: 0 - 5
RBC Morphology	3	Microcytes +	Predominantly: Normocytic/Normochromic; Moderate: Anisocytosis, hypochromia, Microcytosis; Mild: Macrocytosis, Poikilocytosis
Diagnosis	3	Chronic Myeloid Leukemia (Chronic phase).	Chronic Myeloid Leukemia (Chronic Phase)

EQAP Code No.: 1120 Distribution No.: 153-D Month/Year: August/2021 Instrument ID: SYSMEX XN 3100

COMBINED DATA VALUES OF TOTAL PARTICIPANTS

Test parameters	S.No.	Total participants covered in the current dist.	Total No. responded	% of Labs with Z Score 0-2		% of Labs with Z Score 2-3		% of Labs with Z Score >3	
				Among labs	Within lab	Among labs	Within lab	Among labs	Within lab
WBC x10^3/µl	1	317	315	84.76	87.94	3.49	1.59	11.75	9.84
RBC x10^6/µl	1	317	315	92.7	91.11	4.13	3.81	3.17	4.76
Hb g/dl	1	317	315	88.25	91.75	6.67	0.32	5.08	4.44
HCT%	1	317	315	95.24	90.16	2.22	3.49	2.54	6.03
MCV-fl	1	317	315	96.51	92.7	2.22	3.17	1.27	4.13
MCH-Pg	1	317	315	88.57	91.75	8.25	3.49	3.17	4.76
MCHC-g/dl	1	317	315	94.6	88.25	3.49	3.17	1.9	8.57
Plt. x10^3/µl	1	317	315	93.33	90.48	4.44	4.13	2.22	5.4
ReticCount%	2	317	283	90.46	87.63	4.95	6.71	3.89	5.65
PS Assessment	3	317	296	Acceptable:98.65%,Warning Signal:1.35%,Unacceptable :0%					

Comments:

1). Among Lab (EQA) : Results acceptable.

2). Within Lab (IQA) : Precision acceptable.

Note-1: EQA (External Quality Assurance) : Your Performance among various of participating labs in PT, to determine the accuracy of your results.

IQA (Internal Quality Assurance) : Your Performance of comparison of two consecutive measurement values within your lab to test the precision of your autoanalyzer.

Note-2: Z score among & within lab were calculated, as per to ISO/IEC 13528:2015 standard. Z score among lab (EQA)= (Your Result Sum of two values - Consensus Result sum of two values)/(Normalised IQR)

Z score within lab (IQA)= (Your Result Difference of two values - Consensus Result difference of two values)/(Normalised IQR)

IQR = Quartile 3 - Quartile 1 of participant data, Normalised IQR = 0.7413 x IQR

Note-3: Z score 0 to ±2: Acceptable, Z score ±2 to ±3 :Warning Signal, Z score > ±3 : Unacceptable [As per ISO/IEC 13528:2015 standard]

Note-4: Z score value between"0 to ±2" are texted in green colour. Z score value between"±2 to ±3" are texted in orange colour. Z score value > ±3 are texted in red colour.

Note-5: Homogeneity and stability testing of PT sample were done as per ISO 13528:2015 standard. To pass homogeneity test, between sample SD (Ss) should be smaller than the check value (0.3*SDPA). To pass the stability test, average difference in measurement values of first and last day sample ($\bar{x}-\bar{y}$) should be smaller than the check value (0.3*SDPA).

Note-6: ISHTM-AIIMS-EQAP does not subcontract any task of its scheme

Note-7: Participants are free to use methods/analyzer of their own choice.

Note-8: Proficiency testing (PT) samples are sent quarterly to each participant.

Note-9: All the necessary details regarding design and implementation of PT, are provided in the instruction sheet as well as on programme's website www.ishtmaiimseqap.com.

Report authorized by,

Dr. Seema Tyagi (Prof.)

PT Co-ordinator: ISHTM-AIIMS-EQAP

Department of Hematology, AIIMS, New Delhi

-----------End Of Report-----------